EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts

Maria Helena Vaisbich iD, Antônio César Paulillo de Cillo iD, Bárbara Campolina C Silva iD, Catarina Brasil DÁlva iD, Érico Higino de Carvalho iD, Juliana M C M de Almeida, Larissa L M Marques, Marcia Ribeiro iD, Mauro Borghi M da Silva iD, Paula Frassinetti V de Medeiros iD, Pedro Henrique Mendes iD

Molecular Genetics & Genomic Medicine · 2024

DOI: 10.1002/mgg3.2387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Maria Helena Vaisbich und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of São Paulo School of Medicine, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ultragenyx Brasil Farmaceutica Ltda.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disease‐related variants in PHEX cause XLH by an increase of fibroblast growth factor 23 (FGF23) circulating levels, resulting in hypophosphatemia and 1,25(OH) 2 vitamin D deficiency. XLH manifests in early life with rickets and persists in adulthood with osseous and extraosseous manifestations. Conventional therapy (oral phosphate and calcitriol) improves some symptoms, but evidence show that it is not completely effective, and it can lead to nephrocalcinosis (NC) and hyperparathyroidism (HPT). Burosumab (anti‐FGF23 antibody) has shown to be effective and safety in the clinical trials.

Methods

The current real‐world collaborative study evaluated genetic, clinical and laboratory data of XLH Brazilian adult patients treated with burosumab.

Results

Nineteen unrelated patients were studied. Patients reported pain, limb deformities and claudication, before burosumab initiation. 78% of them were previously treated with conventional therapy. The severity of the disease was moderate to severe (15 patients with score >5). At the baseline, 3 patients presented NC (16.7%) and 12 HPT (63%). After 16 ± 8.4 months under burosumab, we observed a significant: increase in stature ( p = 0.02), in serum phosphate from 1.90 ± 0.43 to 2.67 ± 0.52 mg/dL ( p = 0.02); in TmP/GFR from 1.30 ± 0.46 to 2.27 ± 0.64 mg/dL ( p = 0.0001), in 1,25 (OH) 2 D from 50.5 ± 23.3 to 71.1 ± 19.1 pg/mL ( p = 0.03), and a decrease in iPTH from 86.8 ± 37.4 pg/mL to 66.5 ± 31.1 ( p = 0.002). Nineteen variants were found (10 novel ). HPT tended to develop in patients with truncated PHEX variants ( p = 0.06).

Conclusions

This study confirms the efficacy and safety of burosumab on XLH adult patients observed in clinical trials. Additionally, we observed a decrease in iPTH levels in patients with moderate to severe HPT at the baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsAntibodies, Monoclonal, HumanizedAdultHumansAntibodies, MonoclonalBrazilFibroblast Growth FactorsPhosphates

Stichwörter der Autor:innen

FGF23PHEX variantsX-linked hypophosphatemiaadulthoodburosumabhyperparathyroidism

Substanzen

burosumabAntibodies, MonoclonalFibroblast Growth FactorsPhosphatesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University of São Paulo School of Medicine, Sao Paulo, Brazil.
  • Pontifícia Universidade Católica, Campinas, Brazil.
  • Hospital Felício Rocho, Osteometabolism Unit of Santa Casa de Belo Horizonte, Professor of Medicine at University Center of Belo Horizonte - UNIBH, Belo Horizonte, Brazil.
  • Federal University of Ceará, Fortaleza, Brazil.
  • Instituto de Medicina Integrada Professor Fernado Figueira, recife, Federal University of Pernambuco, Recife, Brazil.
  • Federal University of Pernambuco, Recife, Brazil.

ORCID-Profile: Maria Helena Vaisbich, Antônio César Paulillo de Cillo, Bárbara Campolina C Silva, Catarina Brasil DÁlva, Érico Higino de Carvalho, Marcia Ribeiro, Mauro Borghi M da Silva, Paula Frassinetti V de Medeiros, Pedro Henrique Mendes

Förderung

  • Ultragenyx Brasil Farmaceutica Ltda

Zitieren

APA

Vaisbich, M. H., de Cillo, A. C. P., Silva, B. C. C., DÁlva, C. B., de Carvalho, É. H., de Almeida, J. M. C. M., Marques, L. L. M., Ribeiro, M., da Silva, M. B. M., de Medeiros, P. F. V., & Mendes, P. H. (2024). Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.2387

Vancouver

Vaisbich MH, de Cillo ACP, Silva BCC, DÁlva CB, de Carvalho ÉH, de Almeida JMCM, et al. Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.2387

BibTeX
@article{Vaisbich2024,
  author = {Vaisbich, Maria Helena and de Cillo, Antônio César Paulillo and Silva, Bárbara Campolina C and DÁlva, Catarina Brasil and de Carvalho, Érico Higino and de Almeida, Juliana M C M and Marques, Larissa L M and Ribeiro, Marcia and da Silva, Mauro Borghi M and de Medeiros, Paula Frassinetti V and Mendes, Pedro Henrique},
  title = {Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts},
  journal = {Molecular Genetics & Genomic Medicine},
  year = {2024},
  doi = {10.1002/mgg3.2387}
}
Kostenlos starten →